scispace - formally typeset
Journal ArticleDOI

Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.

Gustavo Schvartsman, +11 more
- 01 Oct 2017 - 
- Vol. 112, pp 90-95
Reads0
Chats0
TLDR
In NSCLC patients, the confirmed ORR to single-agent chemotherapy after immunotherapy exposure was higher as compared to historical data from the pre-anti-PD1 era, and approached OrR to first-line platinum-based chemotherapy.
About: 
This article is published in Lung Cancer.The article was published on 2017-10-01. It has received 175 citations till now. The article focuses on the topics: Docetaxel & Lung cancer.

read more

Citations
More filters
Journal ArticleDOI

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

Barbara Burtness, +205 more
- 23 Nov 2019 - 
TL;DR: A randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries finds that pembrolizumab alone improved overall survival and progression-free survival and cetuximab with chemotherapy improved Overall survival in the total population.
Journal ArticleDOI

Novel patterns of response under immunotherapy.

Edith Borcoman, +9 more
- 01 Mar 2019 - 
TL;DR: Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression, and the classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.
Journal ArticleDOI

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Daixi Ren, +28 more
- 30 Jan 2020 - 
TL;DR: The utility of PD-L1 expression levels, mutation burden, immune cell infiltration, and immune cell function for predicting the efficacy ofPD-1/PD-L 1 blockade therapy is described and combination therapies proposed to provide a basis for improved precision medicine are proposed.
Journal ArticleDOI

Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Khalil Saleh, +11 more
- 01 Nov 2019 - 
TL;DR: In R/M SCCHN, the ORR to SCT was high (30%) suggesting that exposure to ICI may increase tumour sensitivity to chemotherapy, and the age at SCT, number of prior chemotherapy regimens, type of chemotherapy before ICI, best response to ICi, site of relapse and Eastern Cooperative Oncology Group at S CT were not associated with response to S CT on univariate analysis.
Journal ArticleDOI

Treatment after progression in the era of immunotherapy

Salem Billan, +2 more
- 01 Oct 2020 - 
TL;DR: This Review focuses on therapeutic approaches for patients who progress on immunotherapy, reviewing the different types of clinical responses associated with immunotherapy and describing treatment options for this population.
References
More filters
Journal ArticleDOI

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Elizabeth Eisenhauer, +15 more
- 01 Jan 2009 - 
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Hossein Borghaei, +27 more
- 21 Oct 2015 - 
TL;DR: Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1, ≥5%, and ≥10%) of the PD-1 ligand.
Journal ArticleDOI

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, +17 more
- 08 Oct 2016 - 
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Journal ArticleDOI

Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

Julie R. Brahmer, +24 more
- 08 Jul 2015 - 
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Roy S. Herbst, +18 more
- 09 Apr 2016 - 
TL;DR: In this article, the authors evaluated the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Related Papers (5)

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Hossein Borghaei, +27 more
- 21 Oct 2015 - 

Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

Julie R. Brahmer, +24 more
- 08 Jul 2015 - 

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, +17 more
- 08 Oct 2016 - 

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, +22 more
- 08 Oct 2016 - 

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Roy S. Herbst, +18 more
- 09 Apr 2016 -